Cargando…

Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom

INTRODUCTION: The glucagon-like peptide-1 receptor agonists liraglutide and lixisenatide are effective at reducing glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM). Although liraglutide has demonstrated superior efficacy in head-to-head clinical trials, real-world...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feher, Michael, Vega-Hernandez, Gabriela, Mocevic, Emina, Buysse, Brian, Myland, Melissa, Power, Geraldine S., Nystrup Husemoen, Lise L., Kim, Joseph, Witte, Daniel R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380503/ https://www.ncbi.nlm.nih.gov/pubmed/28281244 http://dx.doi.org/10.1007/s13300-017-0241-z

Ejemplares similares

Seizure frequency, healthcare resource utilisation and mortality in childhood epilepsy: a retrospective cohort study using the THIN database
por: Myland, Melissa, et al.
Publicado: (2019)

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
por: Ostawal, Amrita, et al.
Publicado: (2016)

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain
por: Mezquita-Raya, Pedro, et al.
Publicado: (2017)

All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK
por: Husemoen, Lise Lotte Nystrup, et al.
Publicado: (2021)

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
por: Hunter, Kerry, et al.
Publicado: (2012)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study
por: Khunti, Kamlesh, et al.
Publicado: (2021)

A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes
por: Melzer-Cohen, Cheli, et al.
Publicado: (2019)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

Lifestyle-Related Factors and Atopy in Seven Danish Population-Based Studies from Different Time Periods
por: Skaaby, Tea, et al.
Publicado: (2015)

IgE sensitization to inhalant allergens and the risk of airway infection and disease: A population-based study
por: Skaaby, Tea, et al.
Publicado: (2017)

Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2023)

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
por: Whyte, Martin B, et al.
Publicado: (2018)

Vitamin D Status and Cause-Specific Mortality: A General Population Study
por: Skaaby, Tea, et al.
Publicado: (2012)

Vitamin D Status and Chronic Obstructive Pulmonary Disease: A Prospective General Population Study
por: Skaaby, Tea, et al.
Publicado: (2014)

Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone
por: Trujillo, Jennifer M., et al.
Publicado: (2018)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol
por: Hinton, William, et al.
Publicado: (2018)

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
por: Becker, Reinhard H. A., et al.
Publicado: (2015)

Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL)
por: Kaneto, Hideaki, et al.
Publicado: (2022)

Cause-Specific Mortality According to Urine Albumin Creatinine Ratio in the General Population
por: Skaaby, Tea, et al.
Publicado: (2014)

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes
por: Barnett, Anthony H
Publicado: (2011)

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
por: Wohlfart, Paulus, et al.
Publicado: (2013)

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
por: Hanefeld, Markolf, et al.
Publicado: (2017)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Occupational Lifting, Fetal Death and Preterm Birth: Findings from the Danish National Birth Cohort Using a Job Exposure Matrix
por: Mocevic, Emina, et al.
Publicado: (2014)

Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine
por: Autio, Henri, et al.
Publicado: (2021)

Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
por: Vega-Hernandez, Gabriela, et al.
Publicado: (2017)

Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
por: Wharton, Sean, et al.
Publicado: (2019)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013)

Prescribing Trends in Bipolar Disorder: Cohort Study in the United Kingdom THIN Primary Care Database 1995–2009
por: Hayes, Joseph, et al.
Publicado: (2011)

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
por: Gluud, Lise L, et al.
Publicado: (2014)

Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials
por: Blonde, Lawrence, et al.
Publicado: (2016)

Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study
por: Brath, Helmut, et al.
Publicado: (2019)

A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes
por: Barrientos‐Pérez, Margarita, et al.
Publicado: (2022)

Propensity‐score‐matched comparative analyses of simultaneously administered fixed‐ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2018)

Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study
por: Bellido, Diego, et al.
Publicado: (2018)

Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study
por: Temelkova, Nataliya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l4g14tf495v6d45e2pdje6lhk5